{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:14:02Z","timestamp":1772759642802,"version":"3.50.1"},"reference-count":9,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["DML"],"published-print":{"date-parts":[[2021,5,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>CYP450 enzymes in the liver have a significant role in the metabolism of\nxenobiotics. Probe drug strategy is broadly used to evaluate the pharmacodynamic and pharmacokinetic\ndrug\/ herb-drug interactions\/ food-drug interactions. Probe drugs reveal the exact pathway of\ndrug metabolism in the liver by their targeted tractability property. The CYP3A4 isoenzyme metabolizes\nthe majority of the drugs (65%).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The characteristics of targeted probe drugs were observed from the admetSAR (version2)\nonline database.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Midazolam is widely used as a probe drug because of its peculiar character. Midazolam affirms\nthe accurate and consistent prediction of pharmacokinetic mediated drug interactions even in\nnanogram concentrations with or without a potent CYP3A inhibitor. Remarkably, midazolam is\nused as a CYP3A4 substrate in the majority of in vivo studies.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>It is concluded that midazolam shows a good response in all clinical studies because\nof its lesser half-life and bioavailability when compared with other probe drugs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1872312814666200811110024","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T08:13:28Z","timestamp":1597220008000},"page":"2-4","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Short Exploration of Selected Sensitive CYP3A4 Substrates (Probe Drug)"],"prefix":"10.2174","volume":"14","author":[{"given":"Sarvesh","family":"Sabarathinam","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, SRM Nagar, Kattankulathur, 603203, Kanchipuram, Chennai, TN, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thangavel M.","family":"Vijayakumar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, SRM Nagar, Kattankulathur, 603203, Kanchipuram, Chennai, TN, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ctcp.2017.12.016","volume":"30","author":"Sarvesh S.","year":"2018","unstructured":"Sarvesh S.; Koushik Muthu Raja M.; Rajanandh M.G.; Seenivasan P.; Prevalence and pattern of usage of complementary and alternative medicine among south Indian asthma patients in a tertiary care hospital. Complement Ther Clin Pract 2018,30(30),103-108","journal-title":"Complement Ther Clin Pract"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s12272-011-1105-0","volume":"34","author":"Na D.H.","year":"2011","unstructured":"Na D.H.; Ji H.Y.; Park E.J.; Kim M.S.; Liu K-H.; Lee H.S.; Evaluation of metabolism-mediated herb-drug interactions. Arch Pharm Res 2011,34(11),1829-1842","journal-title":"Arch Pharm Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1872312813666191120094649","volume":"13","author":"Hu S.X.","year":"2019","unstructured":"Hu S.X.; Mazur C.A.; Feenstra K.L.; Assessment of inhibition of bovine hepatic cytochrome P450 by 43 commercial bovine medicines using a combination of in vitro assays and pharmacokinetic data from the literature. Drug Metab Lett 2019,13(2),123-131","journal-title":"Drug Metab Lett"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1573408016666200218122044","volume":"16","author":"Kaushik R.","year":"2020","unstructured":"Kaushik R.; Khan S.; Sharma M.; Hemalatha S.; Mueed Z.; Nitesh K. Poddar.; Role of cytochrome p450 in prostate cancer and its therapy. Curr Enzym Inhib 2020,16,63","journal-title":"Curr Enzym Inhib"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1872312812666181119154734","volume":"13","author":"Giri P.","year":"2019","unstructured":"Giri P.; Patel H.; Srinivas N.R.; Use of cocktail probe drugs for indexing cytochrome P450 enzymes in clinical pharmacology studies - review of case studies. Drug Metab Lett 2019,13(1),3-18","journal-title":"Drug Metab Lett"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/clpt.2013.27","volume":"93","author":"Halama B.","year":"2013","unstructured":"Halama B.; Hohmann N.; Burhenne J.; Weiss J.; Mikus G.; Haefeli W.E.; A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther 2013,93(6),564-571","journal-title":"Clin Pharmacol Ther"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1021\/acs.jcim.8b00532","volume":"58","author":"Yang Hongbin","year":"2018","unstructured":"Yang Hongbin; Sun Lixia; Wang Zhuang; Li Weihua; Liu Guixia; Tang Yun.; ADMETopt: A Web Server for ADMET Optimization in Drug Design via Scaffold Hopping J Chem Inf Model 2018,58(10),2051-2056","journal-title":"J Chem Inf Model"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1124\/dmd.109.027466","volume":"37","author":"Fisher C.D.","year":"2009","unstructured":"Fisher C.D.; Lickteig A.J.; Augustine L.M.; Ranger-Moore J.; Jackson J.P.; Ferguson S.S.; Cherrington N.J.; Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 2009,37(10),2087-2094","journal-title":"Drug Metab Dispos"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/bcp.12496","volume":"79","author":"Teo Y.L.","year":"2015","unstructured":"Teo Y.L.; Ho H.K.; Chan A.; Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol 2015,79(2),241-253","journal-title":"Br J Clin Pharmacol"}],"container-title":["Drug Metabolism Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/184759","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184759\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/184759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T14:23:54Z","timestamp":1634480634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184759\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,5,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1872312814666200811110024","relation":{},"ISSN":["1872-3128"],"issn-type":[{"value":"1872-3128","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}